Overview

Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin, and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel, doxorubicin, and prednisone together works in treating patients with advanced prostate cancer that has not responded to hormone therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Comprehensive Cancer Center of Wake Forest University
Wake Forest University Health Sciences

Collaborator:

National Cancer Institute (NCI)

Treatments:

Docetaxel
Doxorubicin
Hormones
Liposomal doxorubicin
Prednisone